Bernadette Marquez-Nostra, PhD
Assistant Professor AdjunctDownloadHi-Res Photo
Cards
Appointments
Contact Info
About
Titles
Assistant Professor Adjunct
Biography
Dr. Marquez-Nostra obtained her PhD in Bio-organic Chemistry from the University of California, Davis, and conducted her postdoctoral research in Radiochemistry at Washington University School of Medicine. Dr. Marquez-Nostra's research program focuses on the development of radiolabeled antibodies for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging of cancer in preclinical models and in clinical research. Such approach has the potential to predict response to corresponding targeted therapy and to get a global view of the expression of disease targets in the body non-invasively. Lastly, she is interested in discovering novel probes using phage display peptide/antibody fragment screening of new biomarkers for imaging and treatment of cancer.
Join her team! Positions available for postdocs and postgrads. Email your CV and cover letter.
Appointments
Radiology & Biomedical Imaging
Assistant Professor AdjunctPrimary
Other Departments & Organizations
- Bioimaging Sciences
- Positron Emission Tomography (PET)
- Radiology & Biomedical Imaging
- Yale Cancer Center
- Yale Center for Immuno-Oncology
Education & Training
- Postdoc
- Washington University School of Medicine (2017)
- PhD
- University of California, Davis, Chemistry (2011)
- BS
- California State University (2005)
Research
Overview
Medical Research Interests
Biomedical Research; Positron-Emission Tomography; Radionuclide Imaging; Single Photon Emission Computed Tomography Computed Tomography
ORCID
0000-0001-9024-0750
Research at a Glance
Yale Co-Authors
Frequent collaborators of Bernadette Marquez-Nostra's published research.
Publications Timeline
A big-picture view of Bernadette Marquez-Nostra's research output by year.
Research Interests
Research topics Bernadette Marquez-Nostra is interested in exploring.
Jie Tong, PhD
David Labaree, PhD
David Schoenfeld, MD, PhD
Dijana Djureinovic, PhD, MSc
Fangyong Li, MS, MPH
Harriet Kluger, MD
31Publications
393Citations
Positron-Emission Tomography
Publications
Featured Publications
Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation.
Marquez BV, Beck HE, Aweda TA, Phinney B, Holsclaw C, Jewell W, Tran D, Day JJ, Peiris MN, Nwosu C, Lebrilla C, Meares CF. Enhancing peptide ligand binding to vascular endothelial growth factor by covalent bond formation. Bioconjugate Chemistry 2012, 23: 1080-9. PMID: 22537066, PMCID: PMC3431436, DOI: 10.1021/bc300114d.Peer-Reviewed Original ResearchDevelopment of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor.
Marquez BV, Ikotun OF, Parry JJ, Rogers BE, Meares CF, Lapi SE. Development of a Radiolabeled Irreversible Peptide Ligand for PET Imaging of Vascular Endothelial Growth Factor. Journal Of Nuclear Medicine : Official Publication, Society Of Nuclear Medicine 2014, 55: 1029-34. PMID: 24732153, DOI: 10.2967/jnumed.113.130898.Peer-Reviewed Original Research[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F. [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging And Biology 2016, 18: 952-959. PMID: 27146421, PMCID: PMC5096950, DOI: 10.1007/s11307-016-0951-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHER2-positive breast cancerDose-limiting organPositron emission tomographyBreast cancerMSv/MBqOptimal imaging timeHuman radiation dosimetryPET/CT imagesOrgan time activity curvesGreater tumorTime-activity curvesPurposeThe purposeHuman dosimetryEmission tomographyBiodistribution dataEffective dosePatientsAdverse effectsCancerLiverImaging parametersWomenPresent studyTomographyDaysDevelopment of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer
Cavaliere A, Sun S, Lee S, Bodner J, Li Z, Huang Y, Moores SL, Marquez-Nostra B. Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 48: 383-394. PMID: 32770372, PMCID: PMC7855369, DOI: 10.1007/s00259-020-04978-6.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTriple-negative breast cancerEpidermal growth factor receptorPET/CTMDA-MB-468MDA-MB-231C-MetGrowth factor receptorIsotype controlBreast cancerMDA-MB-468 xenograftsBispecific antibodiesC-Met expression levelsHCC827 lung cancer cellsMono-targeted therapiesFactor receptorLevels of EGFROptimal imaging time pointC-Met expressionNovel bispecific antibodyStandard uptake valueRadioligand binding studiesExpression levelsLung cancer cellsMDA-MB-453Imaging time point[89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer
Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer. Molecular Cancer Therapeutics 2022, 21: molcanther.0590.2021. PMID: 35027482, PMCID: PMC8898259, DOI: 10.1158/1535-7163.mct-21-0590.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsStandardized uptake valueTriple-negative breast cancerWeeks of treatmentCDX-011Tumor modelBreast cancerMelanoma BPretreatment standardized uptake valueAntibody-drug conjugate (ADC) therapyPatient-derived tumor modelsNegative breast cancerSingle bolus injectionPositron emission tomographyTumor regrewPretreatment PETADC therapyPrognostic markerBolus injectionTumor volumeSUV ratioRadiotracer uptakeUptake valueStrong inverse correlationTumor typesPercent change
2024
Nuclear Imaging of Bispecific Antibodies on the Rise
Roohani B, Mendez A, Dangarwala M, Katz S, Marquez-Nostra B. Nuclear Imaging of Bispecific Antibodies on the Rise. Journal Of Nuclear Medicine 2024, 65: 1512-1517. PMID: 39266295, PMCID: PMC11448611, DOI: 10.2967/jnumed.123.267215.Peer-Reviewed Original ResearchPilot PET study of vaginally administered bioadhesive nanoparticles in cynomolgus monkeys: Kinetics and safety evaluation
Grun M, Honhar P, Wang Y, Rossano S, Khang M, Suh H, Fowles K, Kliman H, Cavaliere A, Carson R, Marquez‐Nostra B, Saltzman W. Pilot PET study of vaginally administered bioadhesive nanoparticles in cynomolgus monkeys: Kinetics and safety evaluation. Bioengineering & Translational Medicine 2024, 9 PMCID: PMC11561825, DOI: 10.1002/btm2.10661.Peer-Reviewed Original ResearchConceptsVaginal dosage formsBioadhesive nanoparticlesCynomolgus monkeysAnalysis of inflammatory biomarkersVaginal microbicidesVaginal canalMultiple dosesInflammatory biomarkersTherapeutic efficacyVaginal fluidSystemic circulationLong-term deliveryNoninvasive imagingClinical translationDosage formsNon-human primatesDelivery vehiclesMonkeysDeliveryVaginitisUterusMicrobicidesSafety evaluationBiodistributionDoseMelanocortin-1 Receptor Expression as a Marker of Progression in Melanoma
Su D, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precision Oncology 2024, 8: e2300702. PMID: 38662983, PMCID: PMC11513442, DOI: 10.1200/po.23.00702.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsMC1R expressionMelanoma progressionAssociated with shorter survivalStages of melanoma progressionCases of benign neviChronic sun exposureMarkers of progressionHuman melanoma tissuesBreslow thicknessMelanocortin-1Metastatic melanomaOverall survivalPrimary melanomaMetastatic tumorsMelanoma cohortReceptor expressionPredictive biomarkersAggressive melanomaPrimary lesionTissue microarrayShorter survivalMale sexQuantitative immunofluorescenceBenign neviClinical trials
2023
P-184 Investigation of cell surface murine CD68 as a pan-macrophage biomarker by immunoSPECT and optical imaging
Roohani B, Katz S, Belitzky E, Cavaliere A, Lee S, Rajabimoghadam K, Liu M, Sinusas A, Kluger H, Marquez-Nostra B. P-184 Investigation of cell surface murine CD68 as a pan-macrophage biomarker by immunoSPECT and optical imaging. Nuclear Medicine And Biology 2023, 126: 108651. DOI: 10.1016/j.nucmedbio.2023.108651.Peer-Reviewed Original ResearchConcepts
2022
Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens.
Belitzky E, Cavaliere A, Rajabimoghadam K, Marquez-Nostra B. Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens. Journal Of Visualized Experiments 2022 PMID: 35815982, DOI: 10.3791/63927.Peer-Reviewed Original ResearchCitations
News & Links
News
- February 06, 2019
Meet the Investigator
Related Links
Get In Touch
Contacts
Academic Office Number
Locations
Lippard Laboratory of Clinical Investigation (LLCI)
Academic Office
15 York Street, Fl 6, Rm 609A
New Haven, CT 06510
Appointments
203.737.1376Lippard Laboratory of Clinical Investigation (LLCI)
Lab
15 York Street, Fl 6, Rm 604
New Haven, CT 06510